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The SARS-CoV-2 virus spreading across the world has
led to surges of COVID-19 illness, hospitalizations, and
death. The complex and multifaceted pathophysiology of
life-threatening COVID-19 illness including viral mediated
organ damage, cytokine storm, and thrombosis warrants
early interventions to address all components of the dev-
astating illness. In countries where therapeutic nihilism is
prevalent, patients endure escalating symptoms and with-
out early treatment can succumb to delayed in-hospital
care and death. Prompt early initiation of sequenced mul-
tidrug therapy (SMDT) is a widely and currently available
solution to stem the tide of hospitalizations and death. A
multipronged therapeutic approach includes 1) adjuvant
nutraceuticals, 2) combination intracellular anti-infective
therapy, 3) inhaled/oral corticosteroids, 4) antiplatelet
agents/anticoagulants, 5) supportive care including sup-
plemental oxygen, monitoring, and telemedicine. Ran-
domized trials of individual, novel oral therapies have not
delivered tools for physicians to combat the pandemic in
practice. No single therapeutic option thus far has been
entirely effective and therefore a combination is required
at this time. An urgent immediate pivot from single drug to
SMDT regimens should be employed as a critical strategy
to deal with the large numbers of acute COVID-19 pa-
tients with the aim of reducing the intensity and duration
of symptoms and avoiding hospitalization and death.
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The pandemic of SARS-CoV-2 (COVID-19) is advancing un-
abated across the world with each country and region developing
distinct epidemiologic patterns in terms of frequency, hospitaliza-
tion, and death. There are four pillars to an effective pandemic
response: 1) contagion control, 2) early treatment, 3) hospitaliza-
tion, and 4) vaccination to assist with herd immunity (Fig. 1). Ad-
ditionally, when feasible, prophylaxis could be viewed as an addi-
tional pillar since it works to reduce the spread as well as incidence
of acute illness. Many countries have operationalized all four pil-
lars including the second pillar of early home-based treatment with
distributed medication kits of generic medications and supple-
ments as shown in Table 1. In the US, Canada, United Kingdom,
Western European Union, Australia, and some South American
Countries there has been three major areas of focus for pandemic
response: 1) containment of the spread of infection (masking,
social distancing, etc., 2) late hospitalization and delayed treat-
ments (remdesivir, convalescent plasma, antiviral antibodies), and
3) vaccine development (Bhimraj et al., 2020; COVID-19 Treat-
ment Guidelines, 2020). Thus the missing pillar of pandemic re-
sponse is early home-based treatment (as seen in Fig. 1).
The current three-pronged approach has missed the predom-
inant opportunity to reduce hospitalization and death given the
practice of directing patients to self-isolation at home. Early se-
quential multidrug therapy (SMDT) is the only currently available
method by which hospitalizations and possibly death could be re-
duced in the short term (McCullough et al., 2020a). Most COVID-
19 patients with progressive symptoms who arrive to hospital by
emergency medical services do not require intubation or pressors
initially in the field (Yang et al., 2020). Once hospitalized, if
oxygen is required the mortality rate rises to ~12% (Palazzuoli
et al., 2020). Approximately one quarter require mechanical ven-
til ation, advanced circulatory support, or renal replacement ther-
apy and in that group the mortality exceeds 25% (S. Gupta et al.,
2020a,b). Our observations suggest a majority of hospitalizations
could be avoided with a first treat-at-home strategy with appropri-
ate telemedicine monitoring and access to oxygen and therapeu-
tics. Patients will have the best chance of therapeutic gain when
trea ted before there is significant progression of disease (Argen-
ziano et al., 2020; McCullough et al., 2020b; Rhodes et al., 2017).
The majority serious viral infections require early treatment
with multiple agents and this approach has not been applied in
trials of COVID-19 sponsored by governments or industry. Since
COVID-19 syndrome is characterized by early exponential viral
proliferation, cytokine-mediated organ damage and dysfunction,
and endothelial injury with proximal platelet aggregation with
thrombosis, (Fig. 2) it is not realistic to assume a single drug or an-
tibody could comprehensively handle all of these manifestations.
At this time there are no reports of conclusive randomized trials
of oral ambulatory therapy for COVID-19 and none are expected
in the short term. Most oral therapy trials reported to date have
been small, underpowered, unblinded, relied on biased physician
assigned endpoints, or in some cases, have been administratively
stopped early without scientific justification or safety concerns.
Because COVID-19 is highly communicable, many U.S. am-
bulatory clinics do not care for patients with COVID-19 and stud-
ies suggest there has been little or no attempt to provide outpa-
tient therapy to patients in the period before hospitalization (Price-
Haywood et al., 2020). As the most notable early closure of
a critically needed trial was U.S. National Institutes of Health
study of hydroxychloroquine (HCQ) and azithromycin in ambu-
latory COVID-19 patients after 30 days with only 20 of 2000 bud-
geted patients enrolled (National Institutes of Health, 2020a,b).
There has been no substantive federal effort since then on ambu-
latory trials and thus any future results are not expected in a time
frame to influence public health policy (World Health Organisa-
tion, 2020). At the time of this writing, there are no planned trials
of SMDT regimens designed to manage early viral replication, cy-
tokine storm, and thrombosis in ambulatory patients with COVID-
19 (Fig. 3). Hence, there is an urgent need for innovative early
SMDT in COVID-19 to achieve the goal of reducing the intensity
and severity of symptoms and lessening the risk of hospitalization
or death. This outpatient ambulatory push could have a dramatic
impact on reducing the strain on healthcare systems.
In the absence of evidence from or a commitment to clinical tri-
als of early therapy, other scientific information on the pathophys-
iology, treated natural history, and clinical judgement together
must guide contemporary ambulatory management of COVID-19
(McCullough et al., 2020b). Observational studies reporting out-
comes in patient populations managed consistently with empiri-
cally derived early intervention regimens currently provide an ac-
ceptable level of evidence for safety and efficacy of these widely
available, inexpensive and safe alternatives to the current standard
of non-intervention (Khan et al., 2020). Based on pathophysiology
and observational data, each physician and patient using shared de-
cision making set the course for COVID-19 management: watch-
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Table 1. Listing of early home-based treatment kits provided for acute COVID-19 illness by various countries.
Country Drugs and supplements References
Algeria Chloroquine/Hydroxychloroquine (Belayneh, 2020)
Argentina Ivermectin (Mega, 2020)
Brazil Hydroxychloroquine, Ivermectin, Azithromycin (Vitamin D and zinc only for those
who can afford)
(Coronavirus a Tarde, 2020; Ministério da
Saúde, 2020)
Bangladesh Ivermectin, Doxycycline (Trial Site News, 2020)
Cameroon Chloroquine/Hydroxychloroquine (Belayneh, 2020; Bösmüller et al., 2020)
China Chloroquine/Hydroxychloroquine plus other traditional medicine up to 23 different
Chinese herbal medicines
(Fan et al., 2020)
Colombia Ivermectin (Mega, 2020)
Egypt Chloroquine/Hydroxychloroquine (Mohhamad, 2020)
France Hydroxychloroquine, Azithromycin, and Lopinavir-Ritonavir (Gérard et al., 2020)
Ghana Chloroquine/Hydroxychloroquine (Isaac, 2020)
India Hydroxychlorquine, Ivermectin, alone or in combination with other drugs (Vora et al., 2020)
Korea Hydroxychloroquine (Hong et al., 2020)
Mexico Ivermectin, hydroxychloroquine (Pacheco, 2020)
Morocco Chloroquine/Hydroxychloroquine (Brian, 2020; McFadyen et al., 2020; Mussa,
2020)
Mozanbique Chloroquine/Hydroxychloroquine (Belayneh, 2020; McFadyen et al., 2020)
Nigeria Chloroquine/Hydroxychloroquine (Felix, 2020; McFadyen et al., 2020)
Peru Ivermectin, Azithromycin (Diario oficial del bicentenario, 2020; Trial
Site News, 2020)
Senegal Chloroquine/Hydroxychloroquine (Huaxia, 2020; McFadyen et al., 2020)
South Africa Chloroquine/Hydroxychloroquine (Katharine , 2020; McFadyen et al., 2020)
Spain Patients who are already taking hydroxychloroquine within or outside of clinical tri-
als for COVID-19 as well as patients undergoing chronic treatment with these drugs
should continue taking them and, in any case, maintain their usual follow-ups with
their doctors
(Agencia Española de Medicamentos y Pro-
ductos Sanitarios, 2020)
Taiwan Hydroxychloroquine (Sheng, 2020)
Uganda Chloroquine/Hydroxychloroquine, Azithromycin (McFadyen et al., 2020; The Independent,
2020)
USA No kits provided from public health agencies, Association of American Physicians and
Surgeons Home COVID-19 Treatment Guide recommendends adjuvant neutraceuti-
cals, and sequenced multidrug therapy by prescription
(AAPS, 2020)
ful waiting in self-quarantine or empiric treatment with the aim
of lessening the intensity and duration of symptoms and reduc-
ing the risk of hospitalization and death (Gopalakrishnan et al.,
2020). Fortunately, most healthy individuals with COVID-19 un-
der age 50 years have a self-limited illness and no specific treat-
ment is advised in the absence of severe symptoms. However, they
should be advised that development of lower respiratory symptoms
warrant evaluation of oxygenation status and consideration chest
imaging which may prompt interventions with documentation of
hypoxemia or pulmonary infiltrates.
However, those over age 50 and or those with one or more co-
morbidity have increased risks for hospitalization and death over
1% which increase substantially up to 40% with advancing age
and more medical illnesses (obesity, diabetes mellitus, heart dis-
ease, pulmonary disorders, renal disease, and malignancies) and
thus, warrant early ambulatory treatment according to best med-
ical judgement weighing the benefits and risks of oral therapy.
SARS-CoV-2 as with many viral infections, may be amenable to
multiple drugs early in its course but is less responsive to the same
treatments when administration is delayed and given in the hospi-
tal (Vaduganathan et al., 2020). Innovative SMDT regimens for
COVID-19 utilize principles learned from hospitalized patients as
well as data from treated ambulatory patients.
For the ambulatory patient with recognized signs and symp-
toms of COVID-19 on the first day (Fig. 2), often with nasal real-
time reverse transcription or oral antigen testing not yet performed,
the following three therapeutic principles apply (Centers for Dis-
ease Control and Prevention, 2020) : 1) combination anti-infective
therapy to attenuate viral replication, 2) corticosteroids to modu-
late cytokine storm, and 4) antiplatelet agent/antithrombotic ther-
apy to prevent and manage micro- or overt vascular thrombosis.
For patients with cardinal features of the syndrome (fever, viral
malaise, nasal congestion, loss of taste and smell, dry cough, etc)
with pending or suspected false negative testing, therapy is the
same as those with confirmed COVID-19.
1. Reducing viral spread and contamination
A major goal of self-quarantine is control of contagion
(Nussbaumer-Streit et al., 2020). While there has been a great em-
phasis on masking and social distancing in congregate settings,
many sources of information suggest the main place of viral trans-
mission occurs in the home (respiratory, contact, oral-fecal) (Jef-
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Fig. 1. The four pillars of pandemic response to COVID-19. The four pillars of pandemic response to COVID-19 are: 1) contagion control or efforts
to reduce spread of SARS-CoV-2, 2) early ambulatory or home treatment of COVID-19 syndrome to reduce hospitalization and death, 3) hospitalization
as a safety net to prevent death in cases that require respiratory support or other invasive therapies, 4) natural and vaccination mediated immunity that
converge to provide herd immunity and ultimate cessation of the viral pandemic.
ferson et al., 2020; Xu et al., 2020). Masks for all unaffected con-
tacts within the home as well as frequent use of hand sanitizer
and hand washing is mandatory in the setting when one or more
family members falls ill. Sterilizing surfaces such as countertops,
door handles, phones, and other devices is advised. When possi-
ble, other close contacts canmove out of the house and seek shelter
free of SARS-CoV-2. Findings from multiple studies indicate that
policies concerning control of the spread SARS-CoV-2 are only
partially effective and extension into the home as the most fre-
quent site of viral transfer is reasonable (Hsiang et al., 2020; Xiao
et al., 2020). One of the great advantages of home treatment of
COVID-19 is the ability of an individual or family unit to main-
tain isolation and complete contact tracing. If therapy is offered
in the home with delivery of medications, then trips to urgent care
centers, clinics, and hospitals can be reduced or eliminated. This
limits spread to drivers, other patients, staff, and healthcare work-
ers. On the contrary, therapeutic nihilism on the part of primary
care physicians and health systems drives anxiety and panic among
patients with acute COVID-19 who feel abandoned, making them
more likely to break quarantine and seek aid at urgent care centers,
emergency rooms and hospitals.
SARS-CoV-2 exists outside the human body in a bioaerosol of
airborne particles and droplets. Since exhaled air in an infected
person is considered to be "loaded'' with particulate inoculum,
each exhalation and inhalation in theory reinoculates the nasophar-
ynx and tracheobronchial tree (Chen, 2020). We propose that fresh
circulating air could reduce reinoculation and potentially lessen
the severity of illness and possibly limit household spread during
quarantine (Melikov et al., 2020). This calls for open windows,
fans for aeration, or spending long periods of time outdoors away
from others with no face covering in order to disperse and not re-
inhale the viral bioaerosol. These are principles used in the hospi-
tal with negative pressure ventilation deployed in isolation rooms
to reduce bioaerosol contagion.
2. Adjunctive nutraceuticals
There has been considerable interest and study of the use of
micronutrients and supplements for COVID-19 prophylaxis and
treatment in combination with anti-infectives as first proposed by
Zelenko and colleagues (Derwand et al., 2020). In general these
agents are not curative but assist in treatment regimens to augment
the therapeutic response. The aim of supplementation is to replen-
ish in those with deficiencies associated with COVID-19 mortal-
ity, and to aid in reducing viral replication and tissue damage. Zinc
deficiency is common among adults (Sharma et al., 2020). Zinc
alone is a potent inhibitor of viral replication. Zinc in combina-
tion with hydroxychloroquine (HCQ) is potentially synergistic in
reducing viral replication since HCQ is a zinc ionophore facilitat-
ing intracellular entry and inhibition of intracellular viral replica-
tion (Derwand and Scholz, 2020). This readily available nontoxic
therapy could be deployed at the first signs of COVID-19 (Rahman
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Fig. 2. Major dimensions of COVID-19 infection that call for amulti-drug strategy in the early ambulatory periodwith availablemedications including anti-
infectives (hydroxychloroquine, ivermectin, azithromycin, doxycycline), corticosteroids, and anti-platelet drugs and anticoagulants. The three dimensions
of the infection and their time-course allow for the sequenced multi-drug approach to be utilized with the goal of reducing hospitalization and death.
and Idid, 2020). Zinc sulfate 220 mg (50 mg elemental zinc) can
be taken orally per day (Pormohammad et al., 2020).
Vitamin D deficiency has been associated with increased
COVID-19 mortality and is commonly confounded by increas-
ing age, obesity, diabetes, darker skin tones, and lack of fitness
(Meltzer et al., 2020; Pereira et al., 2020)With good rationale, one
small, randomized trial of vitamin D3 supplementation found re-
duced mortality in patients with COVID-19 (Entrenas et al., 2020;
Zhang et al., 2020a). The suggested dose is 5000 IU of vitamin
D3 per day.
Vitamin C has been used in a variety of viral infections and
could be useful in combination with other supplements in COVID-
19 (Carr andRowe, 2020). Multiple randomized trials of vitaminC
given intravenously or orally are planned or in progress at the time
of this writing (Beigmohammadi et al., 2020; Liu et al., 2020) A
reasonable dose would be vitamin C 3000 mg po qd.
Quercetin is a polyphenol that has a theoretical mechanism
of action that could reduce the activity of a SARS-CoV-2 entry
through the ACE2 receptor, inhibit viral proteases via conveyance
of zinc, and attenuate inflammatory responses mediated through
interleukin-6 (Bastaminejad and Bakhtiyari, 2020; Cione et al.,
2019; Dabbagh-Bazarbachi et al., 2014; Derosa et al., 2020). The
mechanisms of action favorably affect viral replication and im-
mune response, so it is conceivable that this agent taken in combi-
nation with others discussed could play an assistive role in reduc-
ing early viral amplification and tissue damage (Colunga Bian-
catelli et al., 2020). The suggested dose of quercetin is 500 mg po
bid.
3. Anti-infective therapy with intracellular
activity
Quickly reducing the rate, quantity, and duration of viral repli-
cation, is a goal of antiviral therapy aimed at starting on the first
day of symptomatic illness. The compelling rationale for prompt
therapy is to minimize the degree of direct viral injury to the respi-
ratory epithelium, vascular endothelium, and organs (Izzedine et
al., 2020). Maladaptive host responses dependant on replication
of SARS-CoV-2 could be attenuated by early initiation of combi-
nation anti-infectives including activation of inflammatory cells,
cytokines, endothelial injury, and thrombosis (Singhania et al.,
2020). Because SARS-CoV-2 infection is associated with severe
disease and increased mortality in patients over age 50 years and
those with one or more comorbidities, clinicians should use of at
least two commercially available, anti-infective agents where it is
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Fig. 3. Sequential multidrug treatment algorithm for ambulatory acute COVID-19 like and confirmed COVID-19 illness in patients in self-
quarantine. Yr = year, BMI = body mass index, Dz = disease, DM = diabetes mellitus, CVD = cardiovascular disease, chronic kidney disease, HCQ =
hydroxychloroquine, IVM = ivermectin, Mgt = management, Ox = oximetry, reproduced with permission from reference.
appropriately considered clinically indicated, medically necessary
"off-label'' prescription (Shojaei and Salari, 2020). Conversely,
the decision to withhold oral therapy early in a potentially fatal
illness should be made in a shared-decision making process with
the patient given the full understanding that the natural untreated
history of COVID-19 in high risk adults includes the risk of hospi-
talization, hospital-acquired complications, and death. The physi-
cian and patient should understand that the only method by which
a hospitalization could be avoided would be the empiric use of
SMDT that have a reasonable chance of success with acceptable
safety. Recent expanded use authorization of IV administration
of bamlanivimab is another option available to a limited number
of patients, but supplies will be insufficient to treat everyone who
meets the broad criteria for the therapy, so availability of oral al-
ternatives remains essential.
4. Hydroxychloroquine
Hydroxychloroquine (HCQ) is an antimalarial/anti-
inflammatory drug that impairs endosomal transfer of virions
within human cells. HCQ is also a zinc ionophore that conveys
zinc intracellularly to block the SARS-CoV-2 RNA-dependent
RNA polymerase which is the core enzyme of the virus replication
(te Velthuis et al., 2010). A continuously updated synthesis of
HCQ studies supports the following (COVID-19 Treatment,
2020): 1) 63% of studies of HCQ administered late in the hospital
course have demonstrated benefit, 2) 100% of the early treatment
studies have demonstrated benefit with a composite 64% relative
risk reduction in the progression of disease, hospitalization, and
death (Arshad et al., 2020; Mikami et al., 2020; Prodromos and
Rumschlag, 2020; Rosenberg et al., 2020). The small randomized
trials to date are inconclusive for the following reasons: 1) no
placebo control, 2) unblinded, 3) altered primary endpoints, 4)
biased unblinded physician assigned endpoints (such as need for
oxygen), 5) markedly truncated sample sizes and administrative
termination of trials, 6) pretreatment with other antivirals.
Hydroxychloroquine was approved by the U.S. Food and Drug
Administration in 1955, has been used by hundreds of millions
of people worldwide since then, is sold over the counter in many
countries and has a well characterized safety profile (Fram et al.,
2020; Schrezenmeier and Dörner, 2020). Asymptomatic QT pro-
longation is well-recognized though an infrequent (< 1%) occur-
rence with HCQ (Prodromos et al., 2020). In those with glucose-
6-phosphate dehydrogenase deficiency HCQ should not be used
(Aguilar, 2020). In the setting of acute severe COVID-19 ill-
ness, symptomatic arrhythmias can develop in the absence of HCQ
and are attributed to cytokine storm and critical illness (Elsaid et
al., 2020). Data safety and monitoring boards have not declared
safety concerns in HCQ clinical trial published to date. Rare pa-
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tients with a personal or family history of prolongedQT syndrome,
those on additional QT prolonging, contraindicated drugs (e.g.
dofetilide, sotalol), should be treated with caution and a plan to
monitor the QTc in the ambulatory setting. A typical HCQ regi-
men is 200 mg bid for 5 to 30 days depending on continued symp-
toms.
5. Ivermectin
Ivermectin (IVM) is a broad spectrum anti-parasitic agent
that has been shown to have anti-viral activity against a range
of viruses including recently, SARS-CoV-2 (Heidary and Ghare-
baghi, 2020). This drug is well tolerated, has a high therapeutic
index and proven safety profile with over 3.7 billion treatments,
and has been used alone or combined with either doxycycline or
azithromycin in early clinical studies of patients with COVID-19
(Rahman et al., 2020). There are a number of randomized and
prospective studies and all have shown efficacy in clinical out-
comes at the time of this report (Alam et al., 2020; Chowdhury
et al., 2020; Gorial et al., 2020; Khan et al., 2020; Nunez et al.,
2020). Hence, it is reasonable in patients where HCQ cannot be
used and favipiravir is not available, that IVM (200-600 mcg/kg
[6-36 mg] single oral dose given daily or every other day for 2-
3 administrations) could be the base of SMDT intended to reduce
viral replication early in the course of COVID-19. However, uncer-
tainty remains at this time concerning optimal dosing and schedule
(Schmith et al., 2020). In the ICON study, IVM use in the hospi-
tal was associated with a 48% relative risk reduction in COVID-19
mortality (Rajter et al., 2020). Currently, there are 36 randomized
clinical trials of ivermectin alone or in combination for ambulatory
and hospitalized patients listed on clinicaltrials.gov.
6. Favipiravir
Favipiravir is an oral selective inhibitor of RNA-dependent
RNA polymerase, and is approved for ambulatory use in COVID-
19 in multiple countries (Coomes and Haghbayan, 2020). Favipi-
ravir is safe and it shortens viral nasal shedding to less than 7 days
in most studies (Ivashchenko et al., 2020; Pilkington et al., 2020).
A dose administration could be 1600-1800 mg po bid on day 1, fol-
lowing by 600-800 mg po bid for 14 days depending on the dose
sizes available in 30 different countries (Li et al., 2020). At the
time of this writing, there are large ambulatory clinical trials in
progress but are not expected to report in time to aid in the crisis
at hand in the U.S.
7. Antibiotics with intracellular anti-infective
activity
Azithromycin (AZM) is a commonly used macrolide antibiotic
that has antiviral properties mainly attributed to reduced endoso-
mal transfer of virions as well as established anti-inflammatory
effects (Pani et al., 2020). French reports indicated that AZM in
combination with HCQ was associated with reduced durations of
viral shedding, fewer hospitalizations, and reduced mortality as
compared to those untreated (Lagier et al., 2020; Million et al.,
2020). In a large observational inpatient study (n = 2451), those
who received AZM alone had an adjusted hazard ratio for mortal-
ity of 1.05, 95% CI 0.68-1.62, P = 0.83 (Colunga Biancatelli et
al., 2020). The combination of HCQ and AZM has been consid-
ered a standard of care outside the US for COVID-19 in more than
300,000 older adults with multiple comorbidities (Risch, 2020).
AZM like HCQ can prolong the QTc in < 1% of patients, yet has
demonstrated safety in co-administration with HCQ (Huang et al.,
2020). A reasonable regimen is 250 mg po bid for 5 to 30 days for
persistent symptoms or evidence of bacterial superinfection.
Doxycycline is another common antibiotic with multiple intra-
cellular effects that may reduce viral replication, cellular damage,
and expression of inflammatory factors (Malek et al., 2020; Sodhi
and Etminan, 2020). It has been shown to have in vitro activ-
ity against COVID-19 at clinically used concentrations, acting in
post-entry stages of the infection with SARS-CoV-2 in Vero E6
cells (Gendrot et al., 2020). It has also been shown to concen-
trate in the lungs at levels twice that of plasma. When combined
with ivermectin early in the infection it appears to enhance effi-
cacy to near complete eradication of COVID-19 in less than 10
days. This drug has no effect on cardiac conduction and has the
main caveat of gastrointestinal upset and esophagitis. Both AZM
and doxycycline has the advantage of offering antibacterial cover-
age for superimposed bacterial and atypical infection in the upper
respiratory tract (Ailani et al., 1999). Doxycycline can be dosed
200mg po followed by 100mg po bid for 5 to 30 days for persistent
symptoms or evidence of bacterial superinfection.
8. Antibody therapy
Recently, bamlanivimab a monoclonal antibody directed
against the SARS-CoV-2 spike protein has been approved for the
early ambulatory treatment of COVID-19. In the BLAZE-1 ran-
domized trial, the pooled secondary endpoint of COVID-19 hos-
pitalizations occurred 4/136 and 7/69 of the Bamlanivimab and
placebo groups respectively (Chen, 2020). While these results are
not considered conclusive nor robust, given the emergency con-
text, bamlanivimab is authorized for COVID-19 patients who are
12 years of age and older weighing at least 40 kg, and who are at
high risk for progressing to severe COVID-19 or hospitalization.
The authorized dosage for bamlanivimab is a single IV infusion
of 700 mg administered as soon as possible after positive viral test
for SARS-CoV-2 and within 10 days of symptom onset. The in-
fusion should occur over an hour with another hour of monitoring
for systemic reactions (expected < 5%).
A humanized antibody blend of casirivimab and imdevimab
has also received emergency approval in the United States and for a
similar population as bamlanivimab. This pair of antibodies binds
at different regions of the SARS-CoV-2 spike protein. This an-
tibody combination is dosed 1,200 mg of casirivimab and 1,200
mg of imdevimab together as a single IV infusion over at least 60
minutes with another hour of monitoring for reactions (Regeneron
Pharmaceuticals, Inc., 2020). In the phase II program, the sec-
ondary endpoint of hospitalization occurred in 8/434 and 10/231 of
casirivimab/imdevimab and placebo groups, respectively. These
results should be interpreted with caution and cannot be charac-
terized as being conclusive or robust, yet as with all therapies dis-
cussed in this paper, casirivimab/imdevimab can be integrated into
an innovative sequenced multi-drug regimen for SARS-CoV-2 in-
fection.
If SARS-CoV-2 is diagnosed by rapid testing in a facility that
performs antibody infusion such as an emergency room, urgent
care center, or clinic, it is reasonable to start COVID-19 with the
antibody infusion. Conversely, if it can be safely arranged by home
infusion while maintaining quarantine, physicians may prescribe
this therapy to augment the effects of longer courses of oral treat-
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ment. At this time, it is unattractive to ask a patient to break quar-
antine and risk spread of infection to drivers and healthcare per-
sonnel in order to receive an outpatient infusion.
9. Corticosteroids
The manifestations of COVID-19 that prompt hospitalization
and that may well lead to multi-organ system failure are attributed
to a cytokine storm. The characteristic profile of an acutely ill
COVID-19 patient includes leukocytosis with a relative neutrope-
nia. Among COVID-19 patients, serum IL-6 and IL-10 levels are
elevated in the critically ill (Han et al., 2020). In COVID-19, some
of the first respiratory findings are cough and difficulty breathing.
These features are attributable to inflammation and cytokine ac-
tivation. Early use of oral corticosteroids is a rational interven-
tion for COVID-19 patients with these features as they would be in
other inflammatory lung disorders (Kolilekas et al., 2020; Singh
et al., 2020). Inhaled budesonide 1 mg/2 mL via nebulizer or 200
mcg/inhaler up to every four hours can be utilized however, there
are no published reports of efficacy in COVID-19. The RECOV-
ERY trial randomized 6425 hospitalized patients with COVID-19
in a 2 : 1 ratio to open label dexamethasone 6 mg po/IV qd for
up to 10 days and found dexamethasone reduced mortality, HR =
0.65, 95% CI 0.51-0.82, P < 0.001 (Horby et al., 2020) . Con-
cordantly, a meta-analysis involving 1703 critically ill COVID-19
patients found a 36% relative risk reduction in death (Sterne et
al., 2020). Safety concerns regarding prolonged viral replication
with steroids have not been substantiated (Masiá et al., 2020). A
clinical extension of these findings is administration of steroids in
COVID-19 patients at home on day five or beyond with moder-
ate or greater pulmonary symptoms (Szente Fonseca et al., 2020).
Dexamethasone 6 mg po qd or prednisone 1 mg/kg can be given
orally per day for five days with or without a subsequent taper.
10. Colchicine
Colchicine is a non-steroidal anti-mitotic drug used in gout
and pericarditis which blocks metaphase of inflammatory cells
by binding to the ends of microtubules preventing their intracel-
lular assembly. The GRECCO-19 randomized open-label trial in
105 hospitalized patients with COVID-19 (treated with HCQ and
AZM in 98 and 93% respectively) found that colchicine was as-
sociated with a reduction in D-dimer levels and improved clinical
outcomes (Deftereos et al., 2020). The clinical primary end point
(2-point change in World Health Organization ordinal scale) oc-
curred in 14.0% in the control group (7 of 50 patients) and 1.8% in
the colchicine group (1 of 55 patients) (odds ratio, 0.11; 95% CI,
0.01-0.96; P = 0.02) (World Health Organisation, 2020). Because
the short-term safety profile is well understood, it is reasonable to
consider this agent along with corticosteroids in an attempt to re-
duce the effects of cytokine storm and myopericarditis. A dosing
scheme of 0.6 mg po bid x 3 days then 0.6 mg po qd for 30 days
can be considered.
11. Antiplatelet agents and antithrombotics
Multiple studies have described increased rates of pathological
macro and micro-thrombosis (Bösmüller et al., 2020; McFadyen
et al., 2020). COVID-19 patients have described chest heaviness
associated with desaturation that suggests the possibility of pul-
monary thrombosis (Bhandari et al., 2020). Multiple reports have
described elevated D-dimer levels in acutely ill COVID-19 patients
which has been consistently associated with increased risk of deep
venous thrombosis and pulmonary embolism (Artifoni et al., 2020;
Chan et al., 2020; Mestre-Gómez et al., 2020). Autopsy studies
have described pulmonary micro thrombosis and overt embolism
with deep venous thrombus found in over half of fatal COVID-19
cases (Ackermann et al., 2020; Burlacu et al., 2020). These ob-
servations support the hypothesis that a unique endothelial injury
and thrombosis are playing a role in oxygen desaturation, a car-
dinal reason for hospitalization and supportive care (Zhang et al.,
2020b). Because thromboxane A2 is markedly upregulated with
SARS-CoV-2 infection, early administration of aspirin 325 mg per
day is advised for initial antiplatelet and anti-inflammatory effects
(Chow et al., 2020; Glatthaar-Saalmüller et al., 2017; A. Gupta et
al., 2020a; Turshudzhyan, 2020). Ambulatory patients can also be
treated with subcutaneous low-molecular weight heparin or with
oral novel anticoagulant drugs (apixaban, rivaroxaban, edoxaban,
dabigatran) in dosing schemes similar to those used in outpatient
thromboprophylaxis. In a retrospective study of 2773 COVID-19
inpatients, 28% received anticoagulant therapy within 2 days of
admission, and despite being used in more severe cases, antico-
agulant administration was associated with a reduction in mortal-
ity, HR = 0.86 per day of therapy, 95% CI: 0.82-0.89; P < 0.001.
Contemporary use of in hospital anticoagulants has remained in
~30% of cases (Vahidy et al., 2020) . Pre-emptive use of low
molecular weight heparin or novel anticoagulants have been as-
sociated with > 50% reduction in COVID-19 mortality (Billett et
al., 2020). Anticoagulants also reduce death in COVID-19 hospi-
talized patients with thrombotic complications, elevated D-dimer
levels, and higher comorbidity scores (Tang et al., 2020) . Finally,
many acutely ill outpatients also have general indications or risk
for cardioembolic/venous thromboembolic prophylaxis applicable
to COVID-19 (Moores et al., 2020; Ruocco et al., 2020). There are
ambulatory randomized trials of aspirin and novel oral anticoag-
ulants underway. However, given reports of catastrophic stroke
and systemic thromboembolism and the large reductions in mor-
tality for both prophylactic and therapeutic use, administration of
aspirin 325 mg po qd for all COVID-19 high-risk patients and sys-
temic anticoagulation is prudent in patients with a history of heart,
lung, kidney, or malignant disease (Yamakawa et al., 2020).
12. Delivery of oxygen and monitoring
Telemedicine is a tractable means for the initial evaluation and
management of COVID-19 allowing the patient to remain in self-
quarantine at home. Clinical impressions of the patient can be
gained with audio and video feeds. Key supplemental information
includes self/family measurement of vital signs and temperature.
A significant component of safe outpatient management is mainte-
nance of arterial oxygen saturation on room air or prescribed home
oxygen (oxygen concentrators) under direct supervision by daily
telemedicine with escalation to hospitalization for assisted venti-
lation if needed. Self-proning could be entertained for medically
sophisticated patients with good at-home monitoring (Westafer et
al., 2020) .
The interventions discussed in this review could be extended
to seniors in COVID-19 treatment units within nursing homes
and other non-hospital settings. In addition to oral medications,
these centers could deliver intravenous fluid and parenteral medi-
cations (i.e. bamlanivimab, casirivimab/imdevimab), oxygen, and
assisted pressure ventilation with the goal of reducing the risk of
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hospital transfer.
13. Summary
The SARS-CoV-2 outbreak is a once in a hundred-year pan-
demic that has not been addressed by rapid establishment of in-
frastructure amenable to support the conduct of large, randomized
trials in outpatients in the community setting. The early flu-like
stage of viral replication provides a therapeutic window of tremen-
dous opportunity to potentially reduce the risk of more severe se-
quelae in high risk patients. Precious time is squandered with a
"wait and see" approach in which there is no anti-viral treatment
as the condition worsens, possibly resulting in unnecessary hospi-
talization, morbidity, and death. Once infected, the only means of
preventing a hospitalization in a high-risk patient is to apply treat-
ment before arrival of symptoms that prompt paramedic calls or
emergency room visits. Given the current failure of government
support for randomized clinical trials evaluating widely available,
generic, inexpensive therapeutics, and the lack of instructive out-
patient treatment guidelines (U.S., Canada, U.K., Western EU,
Australia, some South American Countries), clinicians must act
according to clinical judgement and in shared decision making
with fully informed patients. Early SMDT developed empirically
based upon pathophysiology and evidence from randomized data
and the treated natural history of COVID-19 has demonstrated
safety and efficacy. In newly diagnosed, high-risk, symptomatic
patients with COVID-19, SMDT has a reasonable chance of ther-
apeutic gain with an acceptable benefit-to-risk profile. Until the
pandemic closes with population-level herd immunity potentially
augmented with vaccination, early ambulatory SMDT should be
a standard practice in high risk and severely symptomatic acute
COVID-19 patients beginning at the onset of illness.
Footnote: To understand which drugs are being used in the
early treatment of COVID-19 in these countries' websites of gov-
ernment agencies such as Brazil, Peru, Spain, Taiwan, and USA
were searched. We also looked for researchers published in
PUBMED by China, France, India, Korea, and African countries.
Additional Information was also obtained from reliable sources of
internet such as Argentina, Bangladesh, Colombia, Mexico and
African Countries.
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